JP2004514654A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004514654A5 JP2004514654A5 JP2002520854A JP2002520854A JP2004514654A5 JP 2004514654 A5 JP2004514654 A5 JP 2004514654A5 JP 2002520854 A JP2002520854 A JP 2002520854A JP 2002520854 A JP2002520854 A JP 2002520854A JP 2004514654 A5 JP2004514654 A5 JP 2004514654A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- blood vessel
- treatment
- acceptable salt
- reduce
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010020772 Hypertension Diseases 0.000 description 2
- 229940122199 Insulin secretagogue Drugs 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- ZHUTVLURGLOKMO-UHFFFAOYSA-N 1-acetylpyrrolidine-2-carbonitrile Chemical compound CC(=O)N1CCCC1C#N ZHUTVLURGLOKMO-UHFFFAOYSA-N 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 1
- 229940122355 Insulin sensitizer Drugs 0.000 description 1
- 206010042957 Systolic hypertension Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64364100A | 2000-08-22 | 2000-08-22 | |
| PCT/EP2001/009587 WO2002015933A2 (en) | 2000-08-22 | 2001-08-20 | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009224224A Division JP2010043101A (ja) | 2000-08-22 | 2009-09-29 | 組合せ |
| JP2012230073A Division JP2013049683A (ja) | 2000-08-22 | 2012-10-17 | 組合せ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004514654A JP2004514654A (ja) | 2004-05-20 |
| JP2004514654A5 true JP2004514654A5 (enExample) | 2012-12-13 |
Family
ID=24581689
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002520854A Withdrawn JP2004514654A (ja) | 2000-08-22 | 2001-08-20 | 組合せ |
| JP2009224224A Withdrawn JP2010043101A (ja) | 2000-08-22 | 2009-09-29 | 組合せ |
| JP2012230073A Withdrawn JP2013049683A (ja) | 2000-08-22 | 2012-10-17 | 組合せ |
| JP2015133314A Pending JP2015205909A (ja) | 2000-08-22 | 2015-07-02 | 組合せ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009224224A Withdrawn JP2010043101A (ja) | 2000-08-22 | 2009-09-29 | 組合せ |
| JP2012230073A Withdrawn JP2013049683A (ja) | 2000-08-22 | 2012-10-17 | 組合せ |
| JP2015133314A Pending JP2015205909A (ja) | 2000-08-22 | 2015-07-02 | 組合せ |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20040034065A1 (enExample) |
| EP (3) | EP2138175A3 (enExample) |
| JP (4) | JP2004514654A (enExample) |
| AR (1) | AR033390A1 (enExample) |
| AT (1) | ATE399010T1 (enExample) |
| AU (1) | AU2001287698A1 (enExample) |
| CL (1) | CL2009001899A1 (enExample) |
| CY (1) | CY1111698T1 (enExample) |
| DE (1) | DE60134575D1 (enExample) |
| DK (1) | DK1351683T3 (enExample) |
| MY (1) | MY141012A (enExample) |
| PE (1) | PE20020617A1 (enExample) |
| PT (1) | PT1351683E (enExample) |
| TW (3) | TWI327468B (enExample) |
| WO (1) | WO2002015933A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| US20060089389A1 (en) | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| US20050234129A1 (en) * | 2002-03-11 | 2005-10-20 | Sutton Paul A | Salts of nateglinide |
| WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| US7232828B2 (en) * | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
| ATE551056T1 (de) * | 2002-12-27 | 2012-04-15 | Takeda Pharmaceutical | Mittel zur hemmung der körpergewichtszunahme |
| TWI349549B (en) * | 2003-04-15 | 2011-10-01 | Sankyo Co | Medicament for treatment of intraocular angiopoietic disease |
| TW200509909A (en) * | 2003-05-16 | 2005-03-16 | Novartis Ag | Use of organic compounds |
| WO2005092319A1 (en) * | 2004-03-29 | 2005-10-06 | Ranbaxy Laboratories Limited | Rapidly disintegrating pharmaceutical compositions comprising nateglinide and a disintegrant |
| EP1751278B1 (en) | 2004-04-29 | 2015-03-18 | U.S. Smokeless Tobacco Company LLC | Nicotiana nucleic acid molecules and uses thereof |
| JP4914714B2 (ja) * | 2004-05-11 | 2012-04-11 | キッセイ薬品工業株式会社 | 脂質代謝異常の予防または治療用医薬組成物 |
| US7588779B2 (en) | 2004-05-28 | 2009-09-15 | Andrx Labs, Llc | Pharmaceutical formulation containing a biguanide and an angiotensin antagonist |
| KR20070073872A (ko) * | 2004-10-07 | 2007-07-10 | 다케다 야쿠힌 고교 가부시키가이샤 | 대사 증후군의 예방 또는 치료용 제제 |
| JP2007099764A (ja) * | 2005-09-09 | 2007-04-19 | Ajinomoto Co Inc | 血糖低下剤 |
| WO2010122927A1 (ja) * | 2009-04-20 | 2010-10-28 | 第一三共株式会社 | 糖尿病由来神経再生遅延の予防又は治療のための医薬 |
| CN110913843B (zh) * | 2017-07-17 | 2022-09-13 | 伊莱利利公司 | 药物组合物 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2951135A1 (de) | 1979-12-19 | 1981-06-25 | Hoechst Ag, 6230 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| JPS6354321A (ja) | 1985-03-27 | 1988-03-08 | Ajinomoto Co Inc | 血糖降下剤 |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| CA1334092C (en) | 1986-07-11 | 1995-01-24 | David John Carini | Angiotensin ii receptor blocking imidazoles |
| ES2207091T3 (es) | 1989-06-14 | 2004-05-16 | Smithkline Beecham Corporation | Acido imidazolil-alquenoico. |
| CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| IL97219A (en) | 1990-02-19 | 1995-12-08 | Ciba Geigy Ag | Biphenyl substituted aliphatic amino compounds process for their preparation and pharmaceutical compositions containing them |
| NZ237476A (en) | 1990-03-20 | 1994-01-26 | Sanofi Sa | N-substituted heterocyclic compounds and pharmaceutical compositions. |
| US5196444A (en) | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| SI9210098B (sl) | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
| US5616599A (en) | 1991-02-21 | 1997-04-01 | Sankyo Company, Limited | Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use |
| AU654331B2 (en) | 1991-03-30 | 1994-11-03 | Kissei Pharmaceutical Co. Ltd. | Succinic acid compounds |
| DK0589874T3 (da) | 1991-06-21 | 2000-04-03 | Boehringer Ingelheim Pharma | Anvendelse af (S) (+) -2-ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl ]aminocarbonylmethyl]-benzoesyre til fremstil |
| ES2100291T3 (es) | 1991-07-30 | 1997-06-16 | Ajinomoto Kk | Cristales de n-(trans-4-isopropilciclohexilcarbonil)-d-fenilalanina y metodos para prepararlos. |
| TW226375B (enExample) | 1991-10-24 | 1994-07-11 | American Home Prod | |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| FI963611A0 (fi) * | 1994-03-17 | 1996-09-13 | Ciba Geigy Ag | Diabeettisen munuaissairauden hoito valsartaanilla |
| AU696868B2 (en) * | 1994-03-29 | 1998-09-17 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles |
| US5488510A (en) | 1994-07-26 | 1996-01-30 | Lemay; Edward J. | Enhanced depth perception viewing device for television |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| SI0914158T2 (sl) * | 1996-04-05 | 2006-04-30 | Takeda Chemical Industries Ltd | Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| GB9613470D0 (en) * | 1996-06-27 | 1996-08-28 | Ciba Geigy Ag | Small solid oral dosage form |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| JPH11315034A (ja) * | 1998-03-04 | 1999-11-16 | Takeda Chem Ind Ltd | アンギオテンシンｉｉ拮抗作用を有する化合物の徐放性製剤、その製造法および用途 |
| FR2778103A1 (fr) * | 1998-04-29 | 1999-11-05 | Sanofi Sa | Compositions pharmaceutiques contenant en association un antagoniste v1a de l'arginine-vasopressine et un antagoniste des recepteurs at1 de l'angiotensine ii |
| MY123337A (en) * | 1998-05-11 | 2006-05-31 | Takeda Chemical Industries Ltd | Oxyiminoalkanoic acid derivatives. |
| ES2552639T3 (es) * | 1998-07-10 | 2015-12-01 | Novartis Pharma Ag | Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos |
| CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| GB0001662D0 (en) * | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| IL148127A0 (en) * | 1999-08-30 | 2002-09-12 | Aventis Pharma Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| TWI302149B (en) * | 1999-09-22 | 2008-10-21 | Bristol Myers Squibb Co | Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method |
| WO2001082916A2 (en) * | 2000-05-03 | 2001-11-08 | Tularik Inc. | Combination therapeutic compositions and methods of use |
| PE20020617A1 (es) * | 2000-08-22 | 2002-08-05 | Novartis Ag | Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina |
| US20020037829A1 (en) * | 2000-08-23 | 2002-03-28 | Aronson Peter S. | Use of DPPIV inhibitors as diuretic and anti-hypertensive agents |
-
2001
- 2001-08-17 PE PE2001000825A patent/PE20020617A1/es not_active Application Discontinuation
- 2001-08-17 AR ARP010103950A patent/AR033390A1/es not_active Application Discontinuation
- 2001-08-20 JP JP2002520854A patent/JP2004514654A/ja not_active Withdrawn
- 2001-08-20 TW TW097122770A patent/TWI327468B/zh not_active IP Right Cessation
- 2001-08-20 AT AT01967289T patent/ATE399010T1/de active
- 2001-08-20 EP EP09171372A patent/EP2138175A3/en not_active Withdrawn
- 2001-08-20 EP EP01967289A patent/EP1351683B1/en not_active Expired - Lifetime
- 2001-08-20 US US10/362,340 patent/US20040034065A1/en not_active Abandoned
- 2001-08-20 DE DE60134575T patent/DE60134575D1/de not_active Expired - Lifetime
- 2001-08-20 TW TW090120391A patent/TWI315197B/zh not_active IP Right Cessation
- 2001-08-20 PT PT01967289T patent/PT1351683E/pt unknown
- 2001-08-20 EP EP08154993A patent/EP1980249A3/en not_active Withdrawn
- 2001-08-20 DK DK01967289T patent/DK1351683T3/da active
- 2001-08-20 TW TW097122772A patent/TWI327469B/zh not_active IP Right Cessation
- 2001-08-20 WO PCT/EP2001/009587 patent/WO2002015933A2/en not_active Ceased
- 2001-08-20 AU AU2001287698A patent/AU2001287698A1/en not_active Abandoned
- 2001-08-21 MY MYPI20013925A patent/MY141012A/en unknown
-
2008
- 2008-09-24 CY CY20081101043T patent/CY1111698T1/el unknown
-
2009
- 2009-09-24 CL CL2009001899A patent/CL2009001899A1/es unknown
- 2009-09-29 JP JP2009224224A patent/JP2010043101A/ja not_active Withdrawn
-
2012
- 2012-10-17 JP JP2012230073A patent/JP2013049683A/ja not_active Withdrawn
-
2015
- 2015-07-02 JP JP2015133314A patent/JP2015205909A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004514654A5 (enExample) | ||
| EP2839832A3 (en) | Use of dipeptidyl peptidase IV inhibitors | |
| JP2007511487A5 (enExample) | ||
| EP2277519A3 (en) | Use of Angiotensin II type 1 receptor antagonists for the prevention of stroke, diabetes and/or congestive heart failure | |
| US20070149451A1 (en) | Combination of a dpp IV inhibitor and an antiobesity or appetite regulating agent | |
| PE20040291A1 (es) | COMBINACION QUE COMPRENDE UN INHIBIDOR DE HMG-CoA-REDUCTASA Y UN POTENCIADOR DE LA SECRECION DE INSULINA Y/O UN SENSIBILIZANTE DE INSULINA | |
| JP2010090173A (ja) | Ｄｐｐｉｖ阻害剤および心臓血管化合物の組み合わせ | |
| JP2007511486A5 (enExample) | ||
| WO2004030611A3 (en) | Non-nucleoside reverse transcriptase inhibitors | |
| EP2039687A4 (en) | THERAPEUTIC OR PROPHYLACTIC AGENT AGAINST MULTIPLE SCLEROSIS | |
| IL190802A0 (en) | Therapeutic combination of amlodipine and benazepril/benazeprilat | |
| WO2005030187A3 (en) | Iloprost in combination therapies for the treatment of pulmonary arterial hypertension | |
| CA2377174A1 (en) | Oral administration forms for administering a fixed tramadol and diclofenac combination | |
| WO1999049854A3 (en) | Use of dexmedetomidine for icu sedation | |
| EP1980249A3 (en) | Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser | |
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびＨＭＧ−Ｃｏ−Ａレダクターゼ阻害剤およびＡＣＥ阻害剤から選択される活性成分を含む組み合わせ | |
| Messerli | Moxonidine: a new and versatile antihypertensive | |
| TW200833321A (en) | Pharmaceutical composition for treating hypertension, diabetes mellitus and cardiovascular diseases | |
| YU57803A (sh) | Upotreba inhibitora il-18 za lečenje i/ili prevenciju srčanih oboljenja | |
| CA2473202A1 (en) | Pharmaceutical composition for regeneration of cirrhotic liver | |
| RU2006135205A (ru) | Применение антагонистов рецептора ангиотензина ii для лечения острого инфаркта миокарда | |
| MX2007004020A (es) | Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica. | |
| WO2004069155A3 (en) | Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof | |
| EA200801305A1 (ru) | Применение циклетанина и других фуропиридинов для лечения гипертензии с преобладанием систолического давления, изолированной систолической гипертензии, повышенного пульсового артериального давления и общей гипертензии | |
| WO2005058310A3 (en) | Use of stating for the treatment of metabolic syndrome |